Industries > Pharma > Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024
Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024
New study shows you commercial prospects for leading eye drug producers
What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 235 page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. We analyse the 38 leading companies for eye medicines, to help you see the future of that industry and market. You will see financial results, interviews, trends, opportunities, and revenue predictions.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
– Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
– Sean Ainsworth, CEO and Founder, RetroSense Therapeutics
– Philip G. Ralston, Jr., CEO, MacuCLEAR
– Dr. Michael Stewart, Associate Professor, Mayo Clinic
– Authority from a company in the industry (views provided anonymously)
Discover forecasts and discussions to help you stay ahead in knowledge
You will find revenue forecasts to 2024 for nine companies, 31 top drugs and the industry, with growth rates and market shares. Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.
You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections further highlight what you will find in our report.
See prospects for leading US manufacturers
Our report provides you with profiles and analyses for top companies based in the US:
There you examine products, progress, results, R&D pipelines and companies' revenue potentials to 2024. Also, you find sales forecasts for brands such as Restasis, Lumigan, Eylea, Combigan and Cosopt.
You can assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you will find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).
What are the outlooks for leading European producers?
Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:
You find outlooks to 2024, including revenue forecasting, as well as R&D and commercial drivers and restraints. Also, you discover sales forecasting for brands such as Lucentis, Avastin, Azopt, Vigamox and Jetrea. We show where sales growth can occur.
What are the prospects for companies based in the Asia-Pacific region?
You see outlooks for top companies developing and producing ocular drugs based in the Asia-Pacific region. Assess product portfolios, other activities and revenue predictions to 2024:
You find sales prospects for brands such as Hyalein, Tapros/Taflotan, Cravit, and Diquas, along with R&D, strategies and driving and restraining forces from 2014 onwards.
Who are the leading emerging companies worldwide?
Our study also covers 29 other companies following after the world leaders. You discover activities of organisations including the following:
• Aerie Pharmaceuticals
• Aerpio Therapeutics
• Alimera Sciences
• Ampio Pharmaceuticals
• Can-Fite BioPharma/OphthaliX
• Chengdu Kanghong Pharmaceutical
• Colby Pharmaceutical
• Eleven Biotherapeutics
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Bioscience
• Otsuka Pharmaceutical
• RXi Pharmaceuticals
You see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss.
You also find revenue predictions for the overall industry segment
Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2024 for five world-level submarkets (therapeutic classes):
• Retinal disorders
• Ophthalmic allergy, inflammation and infection
• Dry eye
• Other agents
We predict total ophthalmic drug revenues to reach $20.9bn in 2014. We forecast high growth there to 2024. Discover the sales potential of the world market and find its most promising segments.
How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 report helps you
In summary, our 235 page report gives you the following knowledge:
• Profiles of 38 leading companies – discover product ranges, recent results, strategies and competition
• Outlooks for companies in eye medicine – assess top players worldwide, seeing opportunities, business data, challenges and commercial outlooks
• Forecasted ophthalmic drug revenues to 2024 for the top 9 companies – find predicted financial results for those medicines
• Predicted revenues of 31 leading drugs to 2024 – see potentials of top products
• Potential revenues to 2024 for the world ophthalmic drug market and 5 product categories (therapeutic classes) – find the industry's sales outlook
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here